OnKure Therapeutics, Inc. (OKUR) stock
OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.58−0.17 (-6.18%)
Close on Nov 17, 2026Market cap $104.48MP/E –Yield –
OnKure Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
OnKure Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$61.74M. For fiscal 2025 it was -$62.50M. The highest annual figure on record is -$19.52M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.50M | – |
| FY2024 | Dec 31, 2024 | -$53.93M | – |
| FY2023 | Dec 31, 2023 | -$36.52M | – |
| FY2022 | Dec 31, 2022 | -$53.76M | – |
| FY2021 | Dec 31, 2021 | -$39.77M | – |
| FY2020 | Dec 31, 2020 | -$19.52M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$16.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.02M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.88M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.58M | -186.8% |
| Q3 FY2024 | Sep 30, 2024 | -$11.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.72M | – |
| Q4 FY2023 | Dec 31, 2023 | $21.40M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.85M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.54M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.00M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.61M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.24M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.09M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.69M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.49M | – |
See a number that looks wrong?